NL-OMON36156已完成不适用
A Phase 1, 2-part, Open Label Pharmacokinetic and Safety Study to Evaluate Dose Proportionality and Accumulation of Firdapse® (3,4-Diaminopyridine Phosphate) after Single and Multiple Oral Doses in Healthy Volunteers - Firdapse® PK study in healthy volunteers
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy male or female
- •Age between 18 and 55 years, inclusive.
- •BMI between 18 and 30 kg/m2, inclusive.
- •Non smoking
排除标准
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of the study. In case of donating any blood or significant loss of blood within 60 days of the start of drug dosing.
研究者
相似试验
进行中（未招募）
1 期
A Phase I randomized, open-label pharmacokinetic comparability study comparing pre- and post-change teclistamab in participants with relapsed/refractory multiple myelomaRelapsed/refractory multiple myelomaCancerISRCTN46766641Janssen-Cilag International NV100
招募中
1 期
A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple MyelomaCTIS2023-508426-10-00Janssen Cilag International100
进行中（未招募）
1 期
A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Efficacy Study of Ascending Doses of Oral CK-101 in Patients with Advanced Solid TumorsEUCTR2017-001265-24-PLCheckpoint Therapeutics, Inc.122
进行中（未招募）
1 期
A Phase 1/2 Study of the Safety and Efficacy of CO-1686 in Patients with Previously Treated EGFR Non-Small Cell Lung CancerPreviously treated NSCLC patients who have documented evidence of an activating mutation in the EGFR gene and have failed treatment with an EGFR inhibitor such as erlotinib or gefitinibMedDRA version: 19.0 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864MedDRA version: 19.0 Level: LLT Classification code 10025048 Term: Lung cancer non-small cell recurrent System Organ Class: 100000004864EUCTR2011-005215-86-PLClovis Oncology, Inc.612
进行中（未招募）
不适用
Open Label Phase II Evaluation of Pharmacokinetics, Efficacy, and Safety of Kedrion Human Plasma-derived Antihaemophilic Double Virus inactivated and Nanofiltered Factor IX Administered to Previously Treated Severe or Moderately Severe Hemophilia B Patients - FIX PK/PDEUCTR2005-006186-14-ITKEDRIO20